JP2014520787A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520787A5
JP2014520787A5 JP2014517822A JP2014517822A JP2014520787A5 JP 2014520787 A5 JP2014520787 A5 JP 2014520787A5 JP 2014517822 A JP2014517822 A JP 2014517822A JP 2014517822 A JP2014517822 A JP 2014517822A JP 2014520787 A5 JP2014520787 A5 JP 2014520787A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517822A
Other languages
English (en)
Japanese (ja)
Other versions
JP6122427B2 (ja
JP2014520787A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/063249 external-priority patent/WO2013004818A1/en
Publication of JP2014520787A publication Critical patent/JP2014520787A/ja
Publication of JP2014520787A5 publication Critical patent/JP2014520787A5/ja
Application granted granted Critical
Publication of JP6122427B2 publication Critical patent/JP6122427B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517822A 2011-07-07 2012-07-06 ダルナビル複合製剤 Active JP6122427B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173067.7 2011-07-07
EP11173067 2011-07-07
PCT/EP2012/063249 WO2013004818A1 (en) 2011-07-07 2012-07-06 Darunavir combination formulations

Publications (3)

Publication Number Publication Date
JP2014520787A JP2014520787A (ja) 2014-08-25
JP2014520787A5 true JP2014520787A5 (enExample) 2015-08-13
JP6122427B2 JP6122427B2 (ja) 2017-04-26

Family

ID=46551505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517822A Active JP6122427B2 (ja) 2011-07-07 2012-07-06 ダルナビル複合製剤

Country Status (24)

Country Link
US (3) US20140142070A1 (enExample)
EP (1) EP2729130B1 (enExample)
JP (1) JP6122427B2 (enExample)
KR (1) KR102058097B1 (enExample)
CN (1) CN103826616B (enExample)
AU (1) AU2012280198B2 (enExample)
BR (1) BR112014000290B1 (enExample)
CA (1) CA2838659C (enExample)
CY (1) CY1121999T1 (enExample)
DK (1) DK2729130T3 (enExample)
EA (1) EA026587B1 (enExample)
ES (1) ES2651212T3 (enExample)
HR (1) HRP20171889T1 (enExample)
HU (1) HUE035241T2 (enExample)
IL (1) IL229933A (enExample)
LT (1) LT2729130T (enExample)
MX (1) MX343689B (enExample)
NO (1) NO2729130T3 (enExample)
PL (1) PL2729130T3 (enExample)
PT (1) PT2729130T (enExample)
RS (1) RS56667B1 (enExample)
SI (1) SI2729130T1 (enExample)
SM (1) SMT201700574T1 (enExample)
WO (1) WO2013004818A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012280198B2 (en) 2011-07-07 2016-12-22 Gilead Sciences, Inc. Darunavir combination formulations
JP2015508822A (ja) * 2012-03-01 2015-03-23 ギリアード サイエンシーズ, インコーポレイテッド 噴霧乾燥製剤
DK2822954T3 (en) 2012-12-21 2016-05-30 Gilead Sciences Inc POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
BR102016026127A2 (pt) 2015-11-09 2017-05-16 Gilead Sciences Inc composições terapêuticas para o tratamento do vírus da imunodeficiência humana
EP3496710A4 (en) * 2016-08-08 2020-03-18 Hetero Labs Limited TABLET COMPOSITION WITH A HIGH ACTIVE SUBSTANCE LOAD FOR TREATING HIV
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
BR112019002120A2 (pt) * 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
US20180085387A1 (en) * 2016-09-27 2018-03-29 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
WO2019018676A1 (en) 2017-07-20 2019-01-24 Janssen Sciences Ireland Unlimited Company COMPOSITIONS COMPRISING DARUNAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FOR USE IN THE TREATMENT OF HIV
US20200101093A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of Treating and Preventing Neuropsychiatric and/or Neurocognitive Complications in Patients Infected with HIV
US20210290590A1 (en) 2020-03-13 2021-09-23 Janssen Sciences Ireland Unlimited Company Methods of treating subjects infected with hiv
CN119700779B (zh) * 2024-11-28 2025-11-04 安徽贝克生物制药有限公司 一种达芦那韦和考比司他复合片剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
WO1995006030A1 (en) 1993-08-24 1995-03-02 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
JP4776775B2 (ja) 1998-06-23 2011-09-21 アメリカ合衆国 Hiv感染哺乳動物を治療するための医薬組成物
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
BRPI0311176B8 (pt) 2002-05-16 2021-05-25 Janssen Sciences Ireland Uc pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP2032536B1 (en) 2006-05-30 2015-05-06 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
AR061838A1 (es) 2006-07-07 2008-09-24 Gilead Sciences Inc Moduladores de propiedades farmacocineticas de terapeuticos
US20080113021A1 (en) * 2006-10-25 2008-05-15 Robert Shen Ibuprofen composition
ES2779826T3 (es) 2007-02-23 2020-08-20 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos
JP2010531301A (ja) * 2007-06-25 2010-09-24 テイボテク・フアーマシユーチカルズ ダルナビル及びエトラビリンを含んでなる組み合わせ調剤
AR069539A1 (es) 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
CN101868454A (zh) 2007-11-20 2010-10-20 詹森药业有限公司 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
PT2296633E (pt) 2008-05-02 2015-12-04 Gilead Sciences Inc A utilização de partículas de portador sólido para melhorar a processabilidade de um agente farmacêutico
CN102307573B (zh) * 2009-02-06 2013-09-11 吉里德科学公司 用于联合治疗的片剂
HRP20170392T1 (hr) * 2009-09-17 2017-06-02 Mylan Laboratories Limited Postupak za pripremu darunavira i njegovog amorfnog oblika
EP2568810B1 (en) 2010-05-10 2018-09-19 Hetero Research Foundation Darunavir compositions
RS55236B1 (sr) 2011-07-07 2017-02-28 Janssen Sciences Ireland Uc Formulacije leka darunavir
AU2012280198B2 (en) 2011-07-07 2016-12-22 Gilead Sciences, Inc. Darunavir combination formulations
WO2013115916A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
AU2015373104B2 (en) 2015-01-03 2020-07-09 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Similar Documents

Publication Publication Date Title
JP2011093937A5 (enExample)
JP2013539946A5 (enExample)
JP2013531034A5 (enExample)
JP2013531018A5 (enExample)
JP2014503786A5 (enExample)
JP2012023335A5 (enExample)
JP2014026276A5 (enExample)
JP2014026274A5 (enExample)
JP2014026275A5 (enExample)
JP2014505137A5 (enExample)
JP2015500269A5 (enExample)
JP2013064178A5 (enExample)
JP2012204203A5 (enExample)
JP2014189812A5 (enExample)
JP2014520787A5 (enExample)
JP2015107586A5 (enExample)
JP2012193264A5 (enExample)
JP2012190699A5 (enExample)
JP2014531903A5 (enExample)
JP2011233516A5 (enExample)
JP2014534151A5 (enExample)
JP2014520786A5 (enExample)
JP2014005521A5 (enExample)
JP2013016377A5 (enExample)
JP2015127764A5 (enExample)